You are here: Home » Companies » News
Business Standard

Dr Reddy's Lab launches heartburn tablet Omeprazole in the US market

Shares of Dr Reddy's were trading 0.20 per cent higher at Rs 2,695 apiece on the BSE

Astrazeneca  |  Medicine  |  Economy Of India

Press Trust of India  |  New Delhi 

medicine, drug, antibiotic, doctor, pharmaceuticals

Dr Reddy's Laboratories Tuesday said it has launched Omeprazole delayed-release tablets, used to treat frequent heartburn, in the US market.

"Dr Reddy's Laboratories has launched Omeprazole delayed-release tablets in the strength of 20 mg, an over-the-counter (OTC) store-brand equivalent of Prilosec tablets, in the US," the company said in a BSE filing.

Milan Kalawadia, Dr Reddy's Laboratories and Head, US OTC and Speciality Rx businesses said, this launch illustrates the company's continued commitment to the OTC business as well as the depth and breadth of its OTC portfolio.

Quoting IRI data, Dr Reddy's Laboratories said the combined market of Prilosec OTC and private label omeprazole OTC products had US retail sales of around USD 492 million for the most recent twelve months ending in October 2018.

Shares of Dr Reddy's were trading 0.20 per cent higher at Rs 2,695 apiece on the BSE.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Tue, December 11 2018. 11:05 IST